YEATS2

Across TCGA pan-cancer cohorts, YEATS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated YEATS2 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher YEATS2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated YEATS2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where YEATS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.521	0.754	.002	42	view →
CCRCC	DFS	Quartile	All	0.943	0.638	.008	8	view →
PDAC	DFS	Median	IV	0.741	0.250	.024	3	view →
LSCC	DFS	Tertile	All	0.970	0.892	.044	2	view →
GBM	DFS	Quartile	All	0.398	0.218	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

YEATS2–HNSC (DFS)

Open the HNSC breakdown →